Laryngectomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Laryngectomy is the surgical removal of the larynx (voice box), performed primarily to treat laryngeal squamous cell carcinoma (SCC) — the most common malignancy of the larynx. It represents a major ablative procedure in head and neck oncology and may be total or partial depending on tumour extent, location, and the surgical team’s judgement about preserving laryngeal function.

The larynx serves three essential functions: phonation (voice production), airway protection during swallowing, and airway patency for breathing. Total laryngectomy sacrifices all three of these functions, creating a permanent tracheostoma through which the patient breathes for life. The trachea is permanently separated from the pharynx and oesophagus. Patients eat and breathe normally through separate routes but require voice rehabilitation to communicate.

Partial laryngectomy aims to remove the tumour while preserving sufficient laryngeal tissue for adequate airway, swallowing, and phonation. Partial procedures include supraglottic laryngectomy (removal of the supraglottic larynx above the true vocal cords), supracricoid laryngectomy with cricohyoidopexy or cricohyoidoepiglottopexy (CHP/CHEP), hemilaryngectomy (vertical partial laryngectomy for unilateral glottic tumours), and transoral laser microsurgery (TLM) for selected early-stage lesions.

The landmark Veterans Affairs (VA) Laryngeal Cancer Study Group trial (1991) and subsequent RTOG 91-11 trial established concurrent chemoradiation (cisplatin plus radiation) as an organ-preservation alternative to total laryngectomy for selected T3 laryngeal cancers, with comparable survival outcomes. This paradigm fundamentally changed the treatment algorithm for advanced laryngeal cancer, reserving total laryngectomy for T4 tumours, radiation failures, or cases where laryngeal function would not meaningfully be preserved.

Laryngectomy is indicated in the following clinical settings:

Malignant Indications

• T3 glottic carcinoma with vocal cord fixation: Tumour extends to the paraglottic space or invades the thyroid cartilage inner cortex, causing vocal cord immobility. Total laryngectomy is the classic treatment, though organ-preservation chemoradiation is appropriate for T3N0-N1 cases with preserved laryngeal function after careful patient selection.
• T4a laryngeal carcinoma: Tumour invades through the outer cortex of the thyroid cartilage, trachea, extrinsic tongue muscles, or thyroid/oesophagus (T4a). Total laryngectomy is the standard of care; concurrent chemoradiation shows inferior locoregional control in T4a disease.
• Recurrent or residual laryngeal cancer after radiotherapy or chemoradiation (salvage laryngectomy): When radiation-based treatment fails, salvage total laryngectomy is the primary curative option. Wound healing complications are more frequent in irradiated fields and require careful surgical planning.
• Chondroradionecrosis or severe laryngeal dysfunction post-radiation: Severe radiation-induced laryngeal necrosis causing life-threatening airway compromise or intractable aspiration may necessitate laryngectomy even in the absence of recurrent cancer.

Non-Malignant Indications

• Intractable aspiration with chronic lung disease (aspiration laryngectomy to protect the airway)
• Severe laryngeal trauma with destruction of laryngeal framework
• End-stage laryngeal stenosis not amenable to reconstruction

Supraglottic laryngectomy targets T1-T2 supraglottic tumours. TLM is appropriate for select T1-T2 glottic and supraglottic tumours in experienced centres.

Laryngectomy — particularly total laryngectomy — is a major ablative procedure requiring comprehensive pre-operative evaluation:

Oncological Staging

Patients undergo CT neck and chest (with contrast), PET-CT for staging of regional and distant disease, and direct laryngoscopy with biopsy under general anaesthesia to confirm diagnosis and define tumour extent. MRI provides superior soft tissue characterisation of tumour invasion into the pre-epiglottic space, paraglottic space, and base of tongue. Clinical staging by AJCC TNM 8th edition guides surgical planning.

Functional Assessment

Pulmonary function tests are essential: patients with a permanent tracheostoma lose the ability to increase subglottic pressure, reducing cough effectiveness. Spirometry, diffusing capacity, and arterial blood gases identify patients who will need particular support with tracheostoma humidification (heat and moisture exchangers, HMEs) to compensate for lost nasal warming and filtering of inspired air.

Nutritional Status

Pre-operative malnutrition significantly increases surgical morbidity. MUST (Malnutrition Universal Screening Tool) score and albumin/prealbumin levels guide pre-operative nutritional optimisation. Nasogastric or percutaneous endoscopic gastrostomy (PEG) feeding is established before surgery in malnourished patients.

Multidisciplinary Team (MDT) Discussion

All patients with laryngeal cancer should be discussed at a specialist head and neck MDT including head and neck surgeon, radiation oncologist, medical oncologist, speech-language pathologist (SLP), dietitian, and clinical nurse specialist. Pre-operative SLP counselling on voice rehabilitation options — TEP, electrolarynx, oesophageal speech — is essential for informed consent and post-operative outcomes.

Contraindications to Surgery

T4b disease (tumour invades prevertebral fascia, encases carotid artery, or invades mediastinal structures) is generally considered unresectable. Severe cardiorespiratory comorbidity may preclude safe anaesthesia. Absolute patient refusal of permanent tracheostoma after full counselling is respected and re-directs care to organ-preservation protocols.

The surgical approach is determined by tumour site, stage, and the surgeon’s experience with each technique.

Total Laryngectomy

Performed under general anaesthesia, total laryngectomy involves complete en-bloc resection of the larynx from the hyoid bone superiorly to the first tracheal ring inferiorly, including the thyroid cartilage, cricoid cartilage, arytenoids, hyoid, and pre-epiglottic fat. The trachea is transected and brought anteriorly to create a permanent end-tracheostoma. The pharynx is closed primarily (T-closure or straight-line closure) or reconstructed if pharyngeal mucosa is deficient. A nasogastric tube is placed for enteral feeding during the 7–10 day healing period before oral intake resumes. Primary TEP (tracheoesophageal puncture) for voice prosthesis placement is frequently performed at the time of total laryngectomy.

Partial Laryngectomy Options

• Supraglottic laryngectomy: Open resection of epiglottis, aryepiglottic folds, and false vocal cords with preservation of true vocal cords. Suitable for T1-T2 supraglottic tumours. Requires good pulmonary reserve due to temporary swallowing dysfunction.
• Supracricoid laryngectomy (SCL): Removes the entire thyroid cartilage, true and false vocal cords, paraglottic spaces, and epiglottis (in CHP) or preserves the epiglottis (in CHEP). One or both arytenoids are preserved. SCL achieves voice and swallowing through arytenoid movement against the tongue base, avoiding permanent tracheostoma in selected patients. Excellent local control for T2-T3 glottic tumours.
• Transoral laser microsurgery (TLM): Endoscopic resection of selected T1-T2 (occasionally T3) glottic tumours using CO2 laser under direct microscopic vision. No neck incision required; same-day or overnight admission for T1 lesions. Oncological outcomes comparable to open partial laryngectomy and radiotherapy for early-stage disease in experienced centres.

Neck Dissection

Regional lymph node management is integral to laryngectomy. Selective neck dissection (levels II-IV) is performed electively for clinically N0 neck when risk of occult nodal metastasis exceeds 15–20%. Modified radical neck dissection (MRND) spares the internal jugular vein, sternocleidomastoid, or accessory nerve when not involved by tumour. Radical neck dissection (all five levels plus IJV, SCM, CN XI) is reserved for bulky N2/N3 disease encasing neurovascular structures.

Reconstruction

Primary closure of the pharynx is feasible in most total laryngectomies without pharyngeal involvement. Defects involving more than one-third of the pharyngeal circumference require reconstruction using a pectoralis major pedicled myocutaneous flap (workhorse of head and neck reconstruction, reliable blood supply via thoracoacromial pedicle) or a free jejunal flap (microvascular anastomosis of the jejunal mesenteric vessels to recipient neck vessels, excellent for circumferential pharyngo-oesophageal defects). Radial forearm free flap and anterolateral thigh flap are alternatives for partial pharyngeal defects.

Loss of the larynx eliminates the natural voice mechanism. Three established methods restore communication:

Tracheoesophageal Puncture (TEP) and Voice Prosthesis

TEP is now the gold standard for voice rehabilitation after total laryngectomy, with intelligible speech achieved in approximately 90% of patients. A small puncture is created in the posterior tracheal wall (primary TEP at the time of laryngectomy, or secondary TEP as a separate procedure). A one-way silicone voice prosthesis — most commonly the Provox Vega (Atos Medical) or Blom-Singer indwelling prosthesis — is inserted into the puncture. The patient covers the tracheostoma with a thumb or HME (hands-free option) and exhales: air diverted through the prosthesis into the oesophagus vibrates the pharyngo-oesophageal (PE) segment, producing a serviceable voice. Prostheses require replacement every 3–6 months as Candida biofilm causes valve failure. The HME (heat and moisture exchanger) system allows hands-free speech and simultaneously filters and humidifies inspired air through the tracheostoma.

Electrolarynx

An electronic device held against the neck or cheek produces an artificial tone that is articulated into speech by the lips and tongue. The electrolarynx is immediately available post-operatively, does not require surgery, and is the primary communication tool while TEP healing occurs. Speech sounds robotic but is intelligible in most communication contexts. Battery-powered devices (e.g., Servox, TruTone) cost USD $400–800.

Oesophageal Speech

The patient learns to inject or swallow air into the oesophagus and belch it back in a controlled manner, vibrating the PE segment to produce sound. Oesophageal speech requires no device or prosthesis, is always available, and produces a characteristic low-pitched voice. However, it is demanding to learn, achievable by only 20–30% of patients to a functional level, and lacks the fluency and volume of TEP speech.

Laryngectomy carries significant perioperative and long-term risks that must be fully discussed during pre-operative counselling:

Early Post-operative Complications

• Pharyngocutaneous fistula: The most common serious complication of total laryngectomy, occurring in 5–30% of cases. Saliva leaks through the pharyngeal repair, producing a cutaneous fistula in the neck. Risk is markedly higher in previously irradiated patients (up to 40%) due to impaired wound healing. Most close spontaneously with wound care and cessation of oral intake; persistent fistulae require surgical repair.
• Wound infection and flap failure: Particularly in irradiated fields. Regular wound surveillance and early antibiotic therapy minimise morbidity.
• Haemorrhage: Rare but potentially life-threatening. Carotid artery blowout — erosion of the carotid by tumour, infection, or radiation — is a surgical emergency requiring urgent vascular control.
• Hypothyroidism: Thyroid gland is sacrificed or devascularised in most total laryngectomies. Lifelong thyroid hormone replacement (levothyroxine) is required and should be initiated within 6 weeks of surgery.

Long-term Complications

• Dysphagia and pharyngoesophageal stricture: Post-operative scarring or post-radiation fibrosis may cause stricture of the neopharynx, requiring serial dilatations. Occurs in up to 20% of salvage laryngectomy cases.
• Tracheostoma stenosis: Narrowing of the tracheostoma requiring dilatation or surgical revision.
• Pulmonary complications: Loss of upper airway conditioning (humidification, warming, filtration) predisposes to chronic bronchitis, mucous plugging, and increased respiratory infections. HME devices substantially mitigate this risk.
• Psychological impact: Permanent tracheostoma, voice loss, and altered body image significantly affect quality of life. Anxiety, depression, and social withdrawal are common. Specialist psychosocial support is integral to rehabilitation.

Post-operative care after total laryngectomy is intensive and multidisciplinary:

Immediate Post-operative Period (Days 1–10)

The patient is nursed in a monitored setting. A cuffed or uncuffed laryngectomy tube maintains tracheostoma patency and is downsized progressively. Nasogastric or PEG feeding continues until pharyngeal healing is confirmed — typically assessed with a water-soluble contrast swallow on day 7–10 post-operatively before oral feeding commences. Wound drains (Jackson-Pratt or corrugated) manage dead space. Daily tracheostoma wound care and secretion management are performed by nursing staff and then taught to the patient.

Tracheostoma Self-Care

Patients learn to clean and change their tracheostoma button or HME base plate daily. Laryngectomy bibs or HME cassettes cover the stoma to humidify inspired air. Swimming and submersion of the head under water are contraindicated without a specialised stoma protector. Stoma covers also prevent inadvertent aspiration of foreign material.

Speech-Language Pathology Rehabilitation

The SLP supervises TEP prosthesis fitting and voice training, oesophageal speech instruction, and dysphagia rehabilitation. Voice therapy begins as soon as the pharyngeal repair is healed and the TEP is fitted (typically 2–6 weeks post-operatively). Multiple sessions over 6–12 weeks are standard.

Oncological Surveillance

Patients are followed every 6–8 weeks for the first year, then every 3 months for years 2–3, and every 6 months thereafter. Clinical examination supplemented by flexible laryngoscopy (to assess the neopharynx and hypopharynx) and CT or PET-CT as clinically indicated. Annual thyroid function tests and chest imaging screen for hypothyroidism and pulmonary metastases.

Adjuvant Therapy

Post-operative radiation (60–66 Gy) or chemoradiation is recommended when histopathology shows positive or close margins, extranodal extension of nodal disease (ENE), perineural invasion, or multiple positive lymph nodes.

Laryngectomy involves significant direct and indirect costs that vary substantially by country and healthcare system:

Hospital and Surgical Costs

• United States: Total laryngectomy with neck dissection costs USD $60,000–150,000 including surgeon fees, anaesthesia, operating theatre, and hospitalisation. Salvage laryngectomy with reconstruction may exceed USD $200,000 in complex cases. Most US patients are covered by Medicare, Medicaid, or private insurance with variable out-of-pocket exposure.
• United Kingdom (NHS): Laryngectomy is provided free at the point of care on the NHS. Private sector costs range from GBP £25,000–60,000 for the complete surgical episode.
• India: Total laryngectomy in major oncology centres (Tata Memorial, AIIMS, Apollo) costs INR 2,50,000–8,00,000 (approximately USD $3,000–10,000), making India a significant destination for international medical tourism for head and neck cancer surgery.
• Thailand / Malaysia / Singapore: USD $15,000–40,000 at major oncology centres with JCI accreditation.

Voice Prosthesis Ongoing Costs

Provox Vega or equivalent voice prostheses cost approximately USD $300–500 per unit; with replacement every 3–6 months, annual prosthesis costs are USD $600–2,000. HME cassettes cost approximately USD $400–800 per year. These ongoing costs may be covered by insurance or require direct patient payment.

Rehabilitation Costs

Speech-language pathology sessions (10–20 sessions post-operatively) add USD $150–300 per session in private settings. Specialist laryngectomy nursing support and psychological counselling add further direct costs. Charity and patient support organisations (e.g., the International Association of Laryngectomees) provide resources and peer support that partially offset formal rehabilitation costs.

The drive to preserve the larynx and maintain natural voice and swallowing has produced several validated non-surgical and minimally invasive alternatives:

Concurrent Chemoradiation (CRT)

The VA Laryngeal Cancer Study Group trial (1991) randomised patients with resectable stage III/IV laryngeal cancer to either induction chemotherapy followed by radiation (with laryngectomy reserved for failures) versus immediate total laryngectomy. Larynx preservation was achieved in 64% of chemotherapy responders, with equivalent 2-year survival. The landmark RTOG 91-11 trial (2003, updated 2013) subsequently established that concurrent cisplatin plus radiation — without induction chemotherapy — achieved superior larynx preservation (88% at 2 years) and locoregional control versus induction chemotherapy or radiation alone. This regimen is now the standard organ-preservation protocol for T3N0-N1 laryngeal SCC.

Important caveats: concurrent CRT is associated with significant acute toxicity (mucositis, dysphagia, xerostomia, radiation-induced hypothyroidism) and long-term dysphagia requiring PEG in up to 40% of cases. A preserved larynx is not synonymous with a functional larynx — patients with severe post-radiation dysphagia have a significantly impaired quality of life and may ultimately benefit from laryngectomy.

Transoral Laser Microsurgery (TLM)

For T1-T2 glottic and selected T2-T3 supraglottic cancers, TLM provides locoregional control rates comparable to radiotherapy and open surgery, with rapid recovery, no tracheostomy, and preservation of voice and swallowing in the majority of patients. TLM is performed by experienced head and neck laser surgeons under general anaesthesia with microsuspension laryngoscopy and CO2 laser resection.

Transoral Robotic Surgery (TORS)

Robotic-assisted endoscopic resection using the da Vinci system is increasingly used for supraglottic tumours and hypopharyngeal lesions in selected centres. TORS provides excellent visualisation and access to anatomical regions difficult to reach via direct laryngoscopy.

Radiation Alone

For T1 glottic carcinoma in situ or T1a vocal cord cancer, radiation alone achieves local control rates of 85–95% with excellent voice quality preservation, and remains an appropriate first-line option.